Search
for
Sort by
Research 21
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Next Generation Therapeutics for Androgenetic Alopecia
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
- Topical solutions for androgenetic alopecia: evaluating efficacy and safety
- Emerging pharmacotherapies for Androgenetic Alopecia
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Androgens/Androgen Receptor in the Management of Skin Diseases
- Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
- Pathophysiology of Androgenetic Alopecia and Implications for Treatment: An Overview of Current Literature
- Recent Advances in Drug Development for Hair Loss
- Updates in Treatment for Androgenetic Alopecia
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer